{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aptose Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"APTO"},"Address":{"label":"Address","value":"251 CONSUMERS ROAD SUITE 1105, TORONTO, Ontario, M2J 4R3, Canada"},"Phone":{"label":"Phone","value":"+1 650 718-5028"},"Industry":{"label":"Industry","value":"Pharmaceuticals and Biotechnology"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies."},"CompanyUrl":{"label":"Company Url","value":"https://www.aptose.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ernest Kitt","title":"Vice President-Development &amp; Technical Operations"},{"name":"Rafael Bejar","title":"Chief Medical Officer &amp; Senior Vice President"},{"name":"Roger Davies","title":"Vice President-Operations"},{"name":"Victor Montalvo-Lugo","title":"Vice President-Clinical Operations"},{"name":"William G. Rice","title":"Chairman, President, CEO &amp; CAO"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}